Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Mirko | Medical Devices | 19.0% | 69th pct | 39 |
| Hospimed Georgia | Medical Devices | 17.5% | 67th pct | 39 |
| Saertashoriso Sameditsi… | Medical Devices | 14.4% | 59th pct | 39 |
| Advanced Medical Techno… | Medical Devices | 8.6% | 46th pct | 39 |
| Viva Group | Medical Devices | — | no FY data | 39 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Advanced Medical Techno… | Saertashoriso Sameditsi… | Mirko | Hospimed Georgia | Viva Group |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 19.4% | 16.5% | 28.2% | 27.4% | — |
| EBITDA Margin | 8.6% | 14.4% | 19.0% | 17.5% | — |
| EBITDAR | 4,298 | 5,718 | 5,576 | 5,113 | — |
| EBITDAR Margin | 8.6% | 14.4% | 19.0% | 17.5% | — |
| EBIT Margin | 8.3% | 14.4% | 17.6% | 17.4% | — |
| Net Profit Margin | 7.2% | 13.4% | 17.9% | 16.9% | — |
| Operating Expense % of Sales | 10.8% | 2.0% | 9.3% | 9.9% | — |
| Returns | |||||
| Return on Assets (ROA) | 8.5% | 63.9% | 21.5% | 31.2% | — |
| Return on Equity (ROE) | 11.0% | 4805.6% | 24.0% | 31.9% | — |
| ROIC [EBIT / Invested Capital] | 14.4% | ||||
| 1595.7% |
| 26.9% |
| 37.1% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.5% | 24.4% | 0.8% | 0.0% | — |
| Debt-to-Equity | 0.01x | 18.38x | 0.01x | 0.00x | — |
| Debt-to-EBITDA | 0.05x | 0.35x | 0.03x | 0.00x | — |
| Equity-to-Assets | 76.9% | 1.3% | 89.7% | 98.0% | — |
| Net Debt | -3,755 | 248 | -2,656 | -1,790 | — |
| Cash & Equivalents | 3,969 | 1,775 | 2,851 | 1,790 | — |
| Total Debt | 214 | 2,022 | 195 | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 4.89x | 1.01x | 8.08x | 42.57x | — |
| Quick Ratio | 2.29x | 0.43x | 3.87x | 42.57x | — |
| Cash Ratio | 0.50x | 0.22x | 1.20x | 6.00x | — |
| Total Current Assets | 39,115 | 8,276 | 19,177 | 12,702 | — |
| Total Current Liabilities | 7,995 | 8,170 | 2,374 | 298 | — |
| Inventory | 20,789 | 4,769 | 9,995 | N/A | — |
| Trade Receivables | 12,146 | 1,733 | 6,282 | 3,569 | — |
| Trade Payables | 5,084 | 6,138 | 2,118 | 298 | — |
| Net Working Capital | 31,121 | 106 | 16,803 | 12,404 | — |
| Net Working Capital % of Revenue | 62.1% | 0.3% | 57.1% | 42.4% | — |
| Trade Working Capital | 27,851 | 364 | 14,159 | 3,271 | — |
| Trade Working Capital % of Revenue | 55.6% | 0.9% | 48.1% | 11.2% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | 1.94x | 6.94x | 2.11x | N/A | — |
| Days Inventory Outstanding (DIO) | 188.0 | 52.6 | 172.9 | N/A | — |
| Receivables Turnover | 4.12x | 22.84x | 4.68x | 8.20x | — |
| Days Sales Outstanding (DSO) | 88.5 | 16.0 | 78.0 | 44.5 | — |
| Payables Turnover | 7.94x | 5.39x | 9.97x | 71.23x | — |
| Days Payable Outstanding (DPO) | 46.0 | 67.7 | 36.6 | 5.1 | — |
| Cash Conversion Cycle | 230.6 days | 0.9 days | 214.2 days | 39.4 days | — |
| Asset Turnover | 1.18x | 4.78x | 1.20x | 1.85x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 4,432 | 5,039 | 5,368 | -550 | — |
| Free Cash Flow (OCF − Capex proxy) | 4,474 | 5,038 | 5,629 | -773 | — |
| Cash Conversion (OCF / EBITDA) | 103.1% | 88.3% | 96.3% | -10.8% | — |
| Dividends Declared | 2,245 | 5,755 | 4,808 | N/A | — |
| Dividend Payout Ratio | 62.3% | 108.8% | 91.5% | N/A | — |